BS_B1HVNV0T
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 29.43495400788436
- age_years
- 1.54
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.576
- PANCREAS_BETA_CELLS+0.473
- KRAS_SIGNALING_DN+0.440
- INTERFERON_GAMMA_RESPONSE+0.380
- HEDGEHOG_SIGNALING+0.356
- SPERMATOGENESIS+0.314
- APICAL_SURFACE+0.223
- ESTROGEN_RESPONSE_EARLY+0.064
- ESTROGEN_RESPONSE_LATE+0.064
- MYOGENESIS+0.053
Top 10 suppressed
- MYC_TARGETS_V1-0.595
- E2F_TARGETS-0.566
- MYC_TARGETS_V2-0.564
- DNA_REPAIR-0.550
- G2M_CHECKPOINT-0.536
- UNFOLDED_PROTEIN_RESPONSE-0.480
- MITOTIC_SPINDLE-0.477
- TGF_BETA_SIGNALING-0.435
- ANGIOGENESIS-0.429
- ADIPOGENESIS-0.356
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311156 | — | — | 0.900 |
| 2 | BS_398KYV92 | Meningioma | — | 0.873 |
| 3 | MDT-AP-0208 | Med | Medulloblastoma | 0.872 |
| 4 | SRR1320916 | GTEX | — | 0.863 |
| 5 | BS_ZR96A4FH | DNET | — | 0.855 |
| 6 | MNG422 | — | — | 0.849 |
| 7 | MNG763 | — | — | 0.848 |
| 8 | C3N-03057 | — | cohortA1 | 0.848 |
| 9 | TCGA-49-AARQ-01A-11R-A41B-07 | — | cohortA1 | 0.847 |
| 10 | SRR1349829 | GTEX | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.576 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.473 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.440 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.356 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.314 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.223 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.064 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.064 | Idelalisib | — uncovered |
| MYOGENESIS | 0.053 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.046 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.027 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |
| COAGULATION | 0.002 | Binimetinib | — uncovered |